Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Breast Neoplasms 5Sarcoma, Endometrial Stromal 1Recurrence 1Perivascular Epithelioid Cell Neoplasms 1Neoplasms by Site 1Neoplasms 1Endometrial Neoplasms 1Central Nervous System Neoplasms 1Central Nervous System Diseases 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Intraductal, Noninfiltrating 1Breast Neoplasms, Male 1Breast Diseases 1Brain Neoplasms 1Brain Diseases 1Adenosarcoma of the uterus 1

Interventions

pembrolizumab 14Paclitaxel 13Carboplatin 12Bevacizumab 7Specimen Handling 6Cisplatin 6olaparib 5Taxes 5Fulvestrant 5Nivolumab 4Megestrol Acetate 4Magnetic Resonance Spectroscopy 4Biopsy 4palbociclib 3durvalumab 3Oxaliplatin 3Leucovorin 3Letrozole 3Immunoglobulin G 3Fluorouracil 3Doxorubicin 3Docetaxel 3Disulfides 3trastuzumab deruxtecan 2ribociclib 2pertuzumab 2lenvatinib 2ipatasertib 2dostarlimab 2capivasertib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Endometrial Neoplasms × elacestrant × 30 days × Clear all
NCT07209449 2026-05-22

A Study of Elacestrant Alone or in Combination With Abemaciclib in People With Endometrial Cancer

Memorial Sloan Kettering Cancer Center

Phase 2 Recruiting
75 enrolled
Gynecologic

Recurrence, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡